ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2136

CD14 Deficiency Delays Progression of Cartilage Degeneration and Protects Against Early Deficits in Functional Outcomes in a Murine Osteoarthritis Model

Nisha Sambamurthy1,2, Vu Nguyen1,2, Ryan Smalley2,3, George R. Dodge3,4 and Carla R. Scanzello1,2,3, 1Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2Translational Musculoskeletal Research Center, CMC Veterans Affairs Medical Center, Philadelphia, PA, 3Department of Orthopedic Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 4Research, CMC Veterans Affairs Medical Center, Philadelphia, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, histopathologic, mouse model and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Biology and Pathology of Bone and Joint - Poster I

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: CD14, though expressed by multiple cell types, is highly expressed by monocytes and macrophages. It forms a complex with Toll-like receptors (TLRs), particularly TLR-2 and TLR-4, thereby facilitating innate inflammatory responses. Elevated expression of CD14 has been associated with joint space narrowing and symptoms in patients with OA (Daghestani et al. 2015). Previous work from our lab has shown that soluble CD14 is present in synovial fluid from patients with knee OA, and sensitizes fibroblast like synoviocytes (FLS) to respond to TLR ligands. The purpose of the current study was to test whether deficiency of CD14 modulates development of structural and functional features of disease using a murine knee OA model

Methods: CD14 deficient mice (CD14-/-) and C57BL/6J congenic controls (WT) were obtained through Jackson Laboratory. 10-12 week old male mice from both strains were subjected to de-stabilization of medial meniscus (DMM), sham surgery or left unoperated. Six and nineteen weeks post-surgery were chosen as early and advanced time points in this model. Groups of 5-9 mice at each timepoint were sacrificed and knee joint histopathology evaluated using the modified OARSI score (Miller RE et al. 2016). As a surrogate for joint pain, changes in spontaneous activity were investigated longitudinally (every 4 weeks, up to 16 weeks) after DMM surgery in the two strains, using the LABORAS® Laboratory animal behavior observation registration and analysis system (Metris B.V., Hoofdorp, The Netherlands).

Results: CD14-/- mice showed similar degrees of cartilage erosion (Mean score ±SEM, 4.667±1.38) as WT controls (4.6±0.6, p>0.9999) at 6 weeks post-DMM. However, by 19 weeks post-DMM, cartilage erosion was significantly reduced in the CD14 knockouts (6.0±0.46) in contrast to their WT counterparts (13.44±2.5, p<0.0001). By contrast at 19 weeks post-DMM, both strains displayed similar osteophytosis (WT: 104.4±23.16; CD14-/-: 138.8±22.48, p=0.15). Analysis of spontaneous activity indicated significant decreases in climbing activity by WT mice at 4 and 8 weeks post-DMM (~84% lesser than baseline). The CD14 deficient mice in contrast maintained climbing activity through the course of 16 weeks after DMM surgery. Furthermore, CD14-/- mice initiated significantly greater number of climbs each hour at 8, 12 and 16 weeks post-DMM as compared to baseline (p≤0.004), and their WT counterparts (p≥0.11).

Conclusion:  Deficiency of CD14 expression significantly diminished progression of cartilage erosion observed in the advanced phase, and protected the mice from early climbing deficits described in this model. No significant protection from osteophytosis was observed. These findings indicate that CD14-mediated mechanisms may be targets to ameliorate symptoms and prevent progression of structural disease. Loss of CD14 appears to affect structural and functional outcomes in this model through different mechanisms over different timelines. Further studies are needed to characterize the cell types involved and the specific mechanisms of action for suitable therapeutic targeting of OA progression.


Disclosure: N. Sambamurthy, None; V. Nguyen, None; R. Smalley, None; G. R. Dodge, None; C. R. Scanzello, None.

To cite this abstract in AMA style:

Sambamurthy N, Nguyen V, Smalley R, Dodge GR, Scanzello CR. CD14 Deficiency Delays Progression of Cartilage Degeneration and Protects Against Early Deficits in Functional Outcomes in a Murine Osteoarthritis Model [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/cd14-deficiency-delays-progression-of-cartilage-degeneration-and-protects-against-early-deficits-in-functional-outcomes-in-a-murine-osteoarthritis-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd14-deficiency-delays-progression-of-cartilage-degeneration-and-protects-against-early-deficits-in-functional-outcomes-in-a-murine-osteoarthritis-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology